Non-invasive Diagnostics of Microbial Keratitis - Trial NCT06364878
Access comprehensive clinical trial information for NCT06364878 through Pure Global AI's free database. This phase not specified trial is sponsored by Sorlandet Hospital HF and is currently Recruiting. The study focuses on Infectious Keratitis. Target enrollment is 125 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Sorlandet Hospital HF
Timeline & Enrollment
N/A
Aug 23, 2023
Apr 08, 2028
Primary Outcome
IVCM findings and cytokine profile in infectious keratitis is specific for the different microbial subtypes.
Summary
Infectious keratitis is a significant cause of partial vision loss and blindness and places a
 large burden on eye care professionals. One of the main challenges for the ophthalmologist
 when presented with a case of suspected microbial keratitis is the determination of the
 subtype of keratitis. It must be determined whether the origin of the infection is bacterial,
 viral, fungal, or parasitic, in order to prescribe a correct, effective treatment aimed at
 the causative pathogen. In daily practice this can be challenging, and general treatments
 with antibiotics are prescribed. Some cases then experiences deterioration, resulting in more
 patients visits and further rounds of invasive treatments and progressive vision
 deterioration.
 
 This project is designed to break this cycle of nonspecific diagnosis, suboptimal treatment,
 and progressive worsening of vision with increased interventions. New, advanced diagnostics
 will be brought into the clinic to provide additional information which, if our hypothesis is
 correct, will result in more rapid and accurate diagnosis of the keratitis subtype. This will
 translate into earlier administration of a more targeted treatment, avoiding the repeated
 round of non-targeted treatment and progressive worsening of the patient's vision. This can
 directly reduce to number of clinic visits and specialist time required for treatment and
 follow-up of keratitis, knowledge of how the eye responds to various microbes by initiating a
 specific cascade of molecular inflammatory signals and changes in protein expression in the
 tear film.
 
 Using in vivo confocal microscopy (IVCM) we will document the cellular status of the cornea
 and identify microbes infecting the cornea in real-time. Secondly, tear samples will be
 obtained from patients with keratitis to evaluate and quantify the molecular cytokine
 signatures associated with specific microbial species, confirmed by microbiological culture.
 We will for the first time develop cytokine profiles for the various types of infection,
 identifying diagnostic cytokines which in the longer term can lead to development of rapid
 point-of-care biomarker diagnostics.
 
 The project aims are translated into the following hypotheses:
 
 H1: In vivo confocal microscopy imaging features detect microbial keratitis consistent with
 clinical assessment and outcome at a greater frequency than microbiological culture results.
 
 H2: Cytokine profiles (or a subset of molecules) in the eye are specific for viral,
 bacterial, fungal, or amoebic keratitis; and H3: A combination of in vivo confocal microscopy
 and molecular profiling of the tear film can yield a specific keratitis diagnosis closely
 matching the clinical progression and outcome of keratitis.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06364878
Non-Device Trial

